Rio Rancho, New Mexico, August 19, 2026
NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through its NTxscribe CORE platform, which is being used by researchers at Baylor College of Medicine to manufacture mRNA for a personalized dendritic cell vaccine currently being evaluated in an industry-sponsored Phase 1 clinical trial for refractory melanoma. The development represents an important translational application of NTx Bio’s continuous-flow manufacturing technology, connecting automated mRNA production with a patient-specific cancer vaccine workflow. The program involves Diakonos Oncology’s DOC1021 (dubodencel) platform, which uses patient-derived tumor material to develop a personalized immune-based treatment approach. For cGxP.wire, the key technology development is the use of an automated manufacturing platform to address one of the most difficult operational steps in producing individualized RNA-based therapeutic material.
Automated mRNA Manufacturing Addresses Personalized Therapy Challenges
At Baylor College of Medicine, NTxscribe CORE is being used to amplify tumor-derived mRNA obtained from small surgical biopsies. The resulting mRNA forms a foundational component of the double-loaded dendritic cell vaccine manufacturing process supporting DOC1021. A major technical focus is preserving the full-length range of the patient’s tumor transcriptome, allowing the manufactured material to retain a broad representation of tumor-derived sequences for incorporation into the personalized vaccine workflow. NTx Bio said the platform is intended to reduce manual intervention in mRNA generation while improving manufacturing consistency. This is particularly relevant for personalized therapies, where every patient’s starting biological material can differ significantly. Unlike conventional manufacturing processes that begin with standardized raw materials, patient-specific cancer vaccine production must accommodate variable biological inputs while maintaining consistent processing and quality expectations.
NTxscribe Technology Supports Clinical Translation
The use of NTxscribe CORE in an active Phase 1 clinical program highlights the potential role of automated RNA manufacturing technologies in moving personalized therapeutic platforms from research environments toward clinical application. NTx Bio’s technology uses a continuous-flow hollow fiber bioreactor architecture to support mRNA amplification, with the company emphasizing automation, reproducibility and reduced batch-to-batch variability. The workflow is designed to minimize hands-on processing and reduce dependence on multiple pieces of equipment and manual unit operations. NTx Bio also highlighted the use of single-use, closed cassettes, which can simplify changeover between patient samples and potentially support higher-throughput manufacturing. These capabilities are particularly relevant to individualized cancer vaccines because manufacturing must be performed repeatedly for different patients while maintaining a controlled and reproducible process.
Advertisement
Personalized Cancer Vaccine Manufacturing Moves Toward Scalable Workflows
The Baylor and Diakonos Oncology collaboration provides a practical example of how biomanufacturing technology can become an important component of personalized cancer therapy development. DOC1021 is being investigated in patients with refractory melanoma, including patients whose disease has stopped responding to standard approaches such as immune checkpoint inhibitors. The vaccine is designed to use a patient’s own tumor-derived information to support an immune response directed toward the cancer. Within this workflow, NTxscribe’s role is concentrated on the mRNA generation and manufacturing step, rather than the clinical efficacy of DOC1021 itself. That distinction is important: the current announcement primarily demonstrates the technology’s integration into a clinical manufacturing workflow and does not establish clinical efficacy of the vaccine. NTx Bio’s broader objective is to provide RNA and protein manufacturing systems capable of supporting applications ranging from personalized doses to larger-scale production, potentially helping developers reduce manufacturing complexity as individualized therapies advance through clinical development..
Source: NTx Bio, press relese
